This week
Suggest a nameObligation Marketing for AI Builders
The 7-Rung LadderThe 8-Type TaxonomyWrapper or WinnerThe Sample ColumnThe Signal
Updated through the day. Every headline links straight to the source. The two lines underneath are ours.
This is the model-to-molecule workflow that biotech founders should be watching. If DeepMind can materially speed up antimicrobial discovery, the applications pipeline across pharma and biodefense just got shorter. The real test is whether candidates from this pipeline actually survive clinical testing.
The real signal here is that foundational science infrastructure is shifting from academic labs to AI companies. Google DeepMind's watermarking of biological systems and the emergence of an AI science economy mean that AI-driven research is moving upstream, into the design phase. If you're building tools for science, you need to understand this layer; if you're investing in science-adjacent AI, you should read the full piece to see which layer has margin.
Watermarking proteins is meaningful because it's a hard problem: you need to embed a signal that survives folding and function. If this scales to production, it becomes table stakes for any biotech AI claim. For builders in bio: this is where the regulatory floor is moving. For infrastructure: watermarking as a whole layer is going to mature fast.